Announcements
- Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
- Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
- Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
- Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
- Medigene to Present at Upcoming Conferences
- Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
- Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein
- Medigene AG reports Financial Results and Business Update for Q1 2024
- Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
- Medigene to Present at Upcoming Scientific Conferences
More ▼
Key statistics
On Friday, Medigene AG (MDG1:HAM) closed at 1.21, 3.43% above its 52-week low of 1.17, set on May 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.21 |
---|---|
High | 1.21 |
Low | 1.21 |
Bid | 1.21 |
Offer | 1.24 |
Previous close | 1.21 |
Average volume | 240.00 |
---|---|
Shares outstanding | 29.48m |
Free float | 28.61m |
P/E (TTM) | -- |
Market cap | 35.37m EUR |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 31 2024 07:16 BST.
More ▼